EUCTR2007-003288-36-ES进行中（未招募）不适用
Ensayo clínico fase 4, multicéntrico, abierto, asesor ciego, de cambio en el cual se evalúa la eficacia y la seguridad de Infliximab (REMICADE®) en pacientes con artritis reumatoide activa que están respondiendo inadecuadamente a Etanercept (ENBREL®) o Adalimumab (HUMIRA®). - RESTART
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- Centocor BV
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Have Active RA, defined as DAS28 score =3.6, at screening visit and at baseline;
- •- Have =6 swollen and = 6 tender joints
- •- Have an inadequate response to treatment with aternecept or adalimumab, at an approved and stable dose in combination with MTX, for a minimum treatment period of at least 3 months prior to the screening visit. The last dose of adalimumab must have been administered at least 2 weeks but not more than 4 weeks prior to the first infliximab infusion. The last dose of etanercept must have been administered at least 1 week before but not more than 2 weeks before the first infliximab infusion.
- •- Are capable of providing written informed consent. Written informed consent must be obtained prior to performing any study-related procedures.
- •- Are willing and able to adhere to the study visit schedule and other protocol-specified procedures.
- •- Are male of female and 18 years or older
- •- Women of childbearing potential must test negative for pregnancy and be using birth control measures during the study and for 6 months after receiving the last administration of infliximab. Likewise, men capable of fathering children must also use appropriate methods of birth control.
- •- Must have decided a stable dose of = 7.5 mg/week MTX for at least 4 weeks prior to screening.
- •- If using NSAIDS for RA, must be on a stable dose for at least 4 weeks before screening.
- •- If using oral corticosteroids, must be on a stable dose equivalent to = 10 mg of prednisone/day for at least 4 weeks before screening. If currently not using corticosteroids, the patient must have not received oral corticosteroids for at least 4 weeks before screening.
- •- Are considered eligible according to the following TB screening criteria:
- •- Have no history of latent of active TB prior to screening;
- •- Have no signs or symptoms suggestive of active TB upon medical history and/or physical examination;
- •- Have had no recent close contact with a person with active TB or, if there has been such contact, will be referred to a physician specializing in TB to undergo additional evaluation to rule out latent or active TB;
- •- Within 1month prior to the first administration of infliximab, have a negative tuberculin skin test, as outlined in Appendix A
- •- The screening laboratory tests must meet the following criteria:
- •- Hemoglobin > 8.5 g/dL
- •- White blood cell (WBC) count > 3.5 x 10,9 cells/L
- •- Neutrophils > 1.5 x 10,9 cells/L
- •- Platelets >100 x 10,9 cells/L
- •- Aspartate aminotransaminase (AST) and alanine aminotransaminase (ALT) levels must be within 2 times the upper limit of normal (ULN) for the laboratory conducting test. Alkaline phosphatase levels must be within 3 times ULN for the laboratory conducting the test.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patients meeting any of the following criteria may not be enrolled in the study:
- •- Have a history of latent or active granulomatous infection, including TB, histoplasmosis, of coccidioidomycosis, prior to screening, or are frequently in contact with individuals who carry active TB infection
- •- Had a Bacille Calmette-Guerin (BCG) vaccination within 12 months of screening;
- •- Have a chest radiograph within 3 months prior to the first administration of infliximab that shows an abnormality suggestive of a malignancy of current active infection, including TB;
- •- Have had a nontubercolous mycobacterial infection of opportunistic infection within 6 months prior to screening;
- •- Have inflammatory diseases other than RA, including but not limited to Psoriatic Arthritis, Ankylosing Spondylitis, systemic lupus erythematosus, or Lyme disease, that might confound the evaluation of the benefit of infliximab therapy;
- •- Are receiving treatment with DMARD/systemic immunosuppressives other than MTX at screening. In patients exposed to leflunomide within the 6 months prior to the screening visit, plasma levels of leflumonide must be < 0.02 mg/L for at least 14 days before screening;
- •- Have ever received infliximab;
- •- Have ever received certolizumab pegol;
- •- Have received treatment with more tha 1 TNFa inhibitor;
- •- Have received treatment with abatacept, alefacept, efalizumab or rituximab during the 3 months prior to screening;
- •- Have used any investigational drug within 3 months prior to screening;
- •- Have or develop a concurrent disease or require medication(s) that could compromise efficacy assessments during the study;
- •- Have a documented HIV infection;
- •- Have documented current active Hepatitis B or a history of documented hepatitis C infection;
- •- Have shown a previous immediate hypersensitivity response, including anaphylaxis, to an immunoglobulin product;
- •- Have a known allergy to murine proteins or other chimeric proteins;
- •- Are pregnant, nursing or planning pregnancy during the trial within the 6-month period thereafter;
- •- Are currently participating or are likely to participate in another investigative trial using an investigational agent, procedure, or medical device during participation in this trial;
- •- Have a current diagnosis or a history of systemic lupus erythematous or lupus-like syndrome; severe, progressive, or uncontrolled renal, hepatic, hematologic, endocrine, pulmonary, cardiac, neurologic, or cerebral diseases;
- •- Have a transplanted organ;
- •- Have had a chronic or recurrent infectious disease including but not limited to chronic renal infection; chronic chest infection; sinusitis; recurrent urinary tract infection; open, draining, of infected skin wound of ulcer;
- •- Have any known malignancy of history of malignancy prior to screening;
- •- Have multiple sclerosis or other central demeylinating disorder;
- •- Have a serious concomitant illness that could interfere with the patient’s participation in the trial;
- •- Have a history of substance abuse within the previous 3 years, history of noncompliance to medical regimens, or other condition/circumstance that could interfere with the patient’s adherence to protocol requirement;
- •- Have a concomitant diagnosis or any history of congestive heart failure;
- •- Are unable of unwilling to undergo multiple venipunctures because of poor tolerability or lack of easy access.
研究者
相似试验
进行中（未招募）
不适用
Ensayo clínico multicéntrico, fase IV, abierto y aleatorizado para evaluar la eficacia de proteinsuccinilato de hierro, frente a sulfato ferroso sesquihidratado, en el tratamiento de la anemia en mujeres embarazadas - FERROGESTEUCTR2004-004180-30-ESHospital Clínic de Barcelona190
进行中（未招募）
不适用
Ensayo clínico abierto, multicéntrico, de 4 meses de duración para evaluar la tolerabilidad,seguridad y resultados de salud de FTY720 en pacientes con formas recurrentes de esclerosismúltipleFormas recurrentes de esclerosis múltipleMedDRA version: 11Level: PTClassification code 10048393Term: Recidiva de esclerosis múltipleEUCTR2010-019029-32-ESovartis Farmacéutica, S.A.1,350
进行中（未招募）
1 期
Ensayo fase 4 multicéntrico, aleatorizado, abierto y comparativo para evaluar los cambios en el diagnóstico de demencia y en la confianza en el diagnóstico tras la realización de DaTSCAN en pacientes con un diagnóstico dudoso de demencia con cuerpos de Lewy (posible DCL)A Multicentre, Randomised, Open-Label, Comparative Phase 4 Trial To AssessChanges in Dementia Diagnostic Category and Diagnostic Confidence AfterDaTSCAN Imaging in Subjects with an Uncertain Diagnosis of Dementia withLewy Bodies (Possible DLB)Pacientes con posible demencia con cuerpos de Lewy (DCL) que pueden cumplir o no criterios de enfermedad de AlzheimerEUCTR2010-021474-11-ESGE Healthcare Ltd. and its Affiliates
进行中（未招募）
1 期
?Ensayo clínico fase IV, prospectivo, multicéntrico, aleatorizado y abierto para evaluar la eficacia y seguridad de GONAL-f® a una dosis basada en las características iniciales de la paciente determinada mediante la calculadora CONSORT, en comparación con una dosis estándar diaria de 150 UI de GONAL-f® para la estimulación ovárica en mujeres sometidas a técnica de reproducción asistida (TRA)?A phase IV prospective, multicentre, randomized, open-label trial to assess the efficacy and safety of GONAL f® at a dose based on subject baseline characteristics determined according to the CONSORT calculator compared with a standard dose of GONAL f® 150 IU per day for ovarian stimulation in women undergoing assisted reproductive technology (ART) - CONSORT en TRAEstimulación ovárica en mujeres sometidas a técnica de reproducción asistida. Ovarian stimulation in women undergoing assisted reproductive technologyMedDRA version: 9.1Level: LLTClassification code 10021930Term: Infertility NOSEUCTR2008-001259-22-ESMerck Serono International S.A.
进行中（未招募）
1 期
Ensayo clínico en fase IV, multicéntrico, aleatorizado, doble ciego y controlado frente a placebo, para evaluar la seguridad y la eficacia de Raptiva® en el tratamiento de pacientes con psoriasis en placas, de moderada a grave, que afecta a las manos y/o a los pies, con o sin pústulasA Phase IV multicentre, randomised, double-blind, placebo controlled, trial to evaluate the safety and efficacy of Raptiva ® in the treatment of subjects with moderate to severe plaque psoriasis involving hands and/or feet, with or without pustules. - Estudio TRUST: Raptiva® en la psoriasis de manos y piesEUCTR2007-004227-37-ESMerck Serono International SA